Regional, circuit and network heterogeneity of brain abnormalities in psychiatric disorders
Monash Health · Monash University · +29 more institutions
Abstract
The substantial individual heterogeneity that characterizes people with mental illness is often ignored by classical case-control research, which relies on group mean comparisons. Here we present a comprehensive, multiscale characterization of the heterogeneity of gray matter volume (GMV) differences in 1,294 cases diagnosed with one of six conditions (attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, depression, obsessive-compulsive disorder and schizophrenia) and 1,465 matched controls. Normative models indicated that person-specific deviations from population expectations for regional GMV were highly heterogeneous, affecting the same area in
Citation impact
- FWCI
- 40.29
- Percentile
- 100%
- References
- 129
Authors
24- ASAshlea SegalCorresponding
Monash Health, Monash University
- LPLinden Parkes
Rutgers, The State University of New Jersey, University of Pennsylvania
- KAKevin Aquino
The University of Sydney, SurveyMonkey (United States), Monash University
- SMSeyed Mostafa Kia
Radboud University Nijmegen, Tilburg University, University Medical Center Utrecht
- TWThomas Wolfers
Oslo University Hospital, Radboud University Nijmegen, University of Oslo, Bernstein Center for Computational Neuroscience Tübingen, University of Tübingen
Topics & keywords
- Neuroscience
- Psychology
- Nerve net
- Neuroimaging
- Psychiatry
- Good health and well-being
Funding
- WFWilson Foundation
- PPfizer
- AAstraZeneca
- SASylvia and Charles Viertel Charitable FoundationAwards: 1197431, 1146292
- NANational Alliance for Research on Schizophrenia and Depression
- WTWellcome TrustAwards: 215698, 215698/Z/19/Z, 1U54MH091657, U54 EB020403
- PFPratt Foundation
- UOUniversity of Cambridge
- UOUniversity of Oxford
- BBBeyond Blue
- DFDeutsche ForschungsgemeinschaftAwards: 513851350, 91619115, 390727645
- UVUniversiteit van Amsterdam
- GDGeneralitat de Catalunya
- NONederlandse Organisatie voor Wetenschappelijk OnderzoekAwards: 012-200-013, 1U54MH091657, 17854, 016130669, 91619115
- EEisai
- SGState Government of VictoriaAward: 1U54MH091657
- MDMinisterio de Ciencia e Innovación
- NFNorges ForskningsrådAwards: 249795, 298646, 276082, 223273, 300767, 802998
- CDCentro de Investigación Biomédica en Red de Salud Mental
- ECEuropean College of Neuropsychopharmacology
- SServier
- HLH. Lundbeck A/S
- RHRamsay Health Care
- ASAustralian Schizophrenia Research Bank
- NINational Institutes of HealthAwards: 1U54MH091657, 223273, EB020403, 802998, COVID-19, U54 EB020403
- AAllergan
- MCMcDonnell Center for Systems NeuroscienceAward: 1U54MH091657
- MRMedical Research CouncilAwards: 1U54MH091657, COVID-19
- NHNational Health and Medical Research CouncilAwards: 1141738, 1024570, 1197431, 1050504, 1146292, 1124472, 1136344, 1156072, 1045354, 1154378, 1118153, 1117188, 1064643, 1006573, 2019101
- HSHelse Sør-Øst RHFAwards: 802998, 2018076, 2019101, 223273
- NINational Institute of Mental HealthAwards: U54 EB020403, 1U54MH091657, K99MH127296, 1156072
- NBNIH Blueprint for Neuroscience ResearchAwards: U54 EB020403, 1U54MH091657